Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors a controlled observational study

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 634-640

  Liavaag, Astrid Helene ^a,d   Tonstad, Serena ^b   Pripp, Are H ^c   Tropé, Claes ^b   Lrum, Anne D ^b  

^a Department of Gynecology   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Sorlandet Hospital   (Norway)

Author keywords

Controlled study; Coronary heart disease; Epithelial ovarian cancer survivors; Framingham risk score; Metabolic syndrome

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CALCULATION; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; EDUCATION; FEMALE; FOLLOW UP; HEALTH; HEALTH CARE PERSONNEL; HISTORY; HOSPITAL; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OVARIECTOMY; OVARY CANCER; POPULATION; PREVALENCE; PRIORITY JOURNAL; RISK; SCORING SYSTEM;

ADULT; AGED; CASE-CONTROL STUDIES; EPITHELIAL CELLS; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREVALENCE; RISK FACTORS; SURVIVORS; YOUNG ADULT;

EID: 67651011873     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a13058     Document Type: Article

References (30)

1. Lockwood-Rayermann S. Survivorship issues in ovarian cancer: a review. Oncol Nurs Forum. 2006;33:553-562.
2. Kristensen GB, Trope C. Epithelial ovarian cancer. Lancet. 1997; 349:113-117.
3. Cancer Registry of Norway. Cancer in Norway 2006. Cancer Incidence, Mortality, Survival and Prevalence in Norway. Oslo, Norway: Cancer Registry of Norway; 2007.
4. Pansini F, Bonaccorsi G, Calisesi M, et al. Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturitas. 1993;17:181-190.
5. Lobo RA. Surgical menopause and cardiovascular risks. Menopause. 2007;14:562-564.
6. DLrum A, Tonstad S, Liavaag A, et al. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol. 2008;109:377-383.
7. Akahoshi M, Soda M, Nakashima E, et al. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation. 1996;94:61-66.
8. Mack WJ, Slater CC, Xiang M, et al. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril. 2004;82: 391-397.
9. Schwab N. Risk of coronary heart disease, dietary fat modification, stage of change, and self-efficacy in surgical and naturally postmenopausal women. J Womens Health Gend Based Med. 2000; 10:1089-1100.
10. de Vos F, Nuver J, Willemse A, et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage. Eur J Cancer. 2004;40: 696-700.
11. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet. 1992;339:1154-1156.
12. Heller RF. Coronary heart disease, cancer, lipoproteins, and the effects of clofibrate: is induction a common link and are lipoproteins red herrings? Lancet. 1981;8258:1258-1260.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
14. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe. Eur Heart J. 2003;24: 987-1003.
15. The IDF consensus worldwide definition of the metabolic syndrome. Available at: http://www.idf.org. Accessed September 21, 2006.
16. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
17. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-new worldwide definition. Lancet. 2005;366:1059-1062.
18. Sacks J. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry. 2004;65:1-12.
19. Hildrum B, Mykletun A, Midthjell K, et al. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 Study. BMC Public Health. 2007;7:220.
20. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
21. Berek JS, Hacker NF. Practical Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005:443-494.
22. Norwegian University of Technology and Science. The HUNT Research Center. Available at: http://www.hunt.ntnu.no.
23. Holmen J, Midthjell K, Krüger Ö, et al. The Nord-Tröndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Nor Epidemiol. 2003;13:19-32.
24. Thorsen L, Nystad W, Stigum H, et al. The association between self-reported physical activity and prevalence of depression and anxiety in long-term survivors of testicular cancer and in general population sample. Support Care Cancer. 2005;13:637-646.
25. Schwartz CE, Sprangers MAG. Adaptation to Changing Health. 1st ed. Washington, DC: American Psychological Association; 2000: 25-36.
26. Å kesson A, Weismayer C, Newby PK, et al. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. Arch Intern Med. 2007;167:2122-2127.
27. Sogaard AJ, Selmer R, Bjertness E, et al. The Oslo Health Study: the impact of self-selection in a large, population-based survey. Int J Equity Health. 2004;3:3.
28. Selmer R, Sogaard AJ, Bjertness E, et al. The Oslo Health study: reminding the non-responders-effects on prevalence estimates. Nor Epidemiol. 2003;13:89-94.
29. Gotay C, Kawamoto C, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355-1363.
30. Brett KM, Madans JH. Hysterectomy use: the correspondence between self-reports and hospital records. Am J Publ Health. 1994;84:1653-1655.